Home GPCR & G Protein CCR

CCR Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S8512 Cenicriviroc Cenicriviroc is a potent, orally active dual inhibitor of CC chemokine receptor 2 (CCR2) and CCR5. This compound also inhibits HIV-1 and HIV-2 with potent anti-inflammatory and antiinfective activity.
Nature, 2025, 10.1038/s41586-024-08535-1
Int J Biol Sci, 2023, 19(8):2572-2587
Stem Cells, 2023, 41(6):672-683
S2004 Vicriviroc Malate Vicriviroc is a potent CCR5 antagonist with IC50 of 0.91 nM, showing broad-spectrum activity against genetically diverse HIV-1 isolates, and also drug-resistant viruses with RTI, PRI, or MDR phenotypes. Phase 3.
Nature, 2013, 493(7430):51-5
Cancer Res, 2012, 72(15):3839-50
J Antimicrob Chemot, 2011, 66(4):802-12
Verified customer review of Vicriviroc Malate
S3479 R243 R243 is an inhibitor of Chemokine (C-C motif) receptor 8 (CCR8) signaling and chemotaxis.
Cell Proliferation, 2025, e70032
Cell Prolif, 2025, e70032.
Journal of Experimental Medicine, 2019, 2763–2777
S2907 Pirfenidone Pirfenidone is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Pirfenidone attenuates chemokine (CC motif) ligand-2 (CCL2) and CCL12 production with anti-fibrotic activity. Phase 3.
Biomed Pharmacother, 2025, 188:118216
Eur Respir J, 2024, 2300580
Phytomedicine, 2024, 135:156051
Verified customer review of Pirfenidone
S3032 Bindarit (AF 2838) Bindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.
Exp Mol Med, 2024, 56(2):408-421.
PLoS Pathog, 2024, 20(11):e1012747
J Biol Chem, 2023, S0021-9258(23)02393-1
Verified customer review of Bindarit (AF 2838)
S3205 Perillaldehyde Perillaldehyde (Perilladehyde, Perillal, PAE, PA), the main component of Perilla frutescens (a traditional medicinal antioxidant herb), inhibits BaP-induced AHR activation and ROS production, inhibits BaP/AHR-mediated release of the CCL2 chemokine, and activats the NRF2/HO1 antioxidant pathway.
Front Cell Dev Biol, 2025, 13:1598520
S0777 Isuzinaxib (APX-115 free base) Isuzinaxib (APX-115 free base, Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. This compound significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney.